drugset / Trial / NCT05574387
Metformin as Added on Therapy in Patients With Ulcerative Colitis
Phase 2
Recruiting
46 enrolled
Tanta University
Principal Investigator Mostafa Mahmoud Bahaa El-Dien Pharmacy Practice Department- Horus University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is marked by increased intestinal motility and bloody diarrhea. The clinical value of existing therapeutic strategies of UC, including glucocorticoids, anti-tumor necrosis factor α (TNF-α), mesalamine, and thiopurines is still limited. Therefore, the discovery of new therapeutic approaches is essential to improve the effectiveness of the treatment.Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a conserved fuel-sensing enzyme that plays an important role in the regulation of cellular metabolism where it increases glucose and fatty acids uptake and activates the oxidation process to improve the cellular energy utilization
Timeline
- Start
- 2023-01-20
- Primary completion
- 2026-12
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Metformin | Small molecule | 500 mg | — |